DMD and Duchenne muscular dystrophy: This Phase 2a, short-term study conducted from Dec 2005 to May 2007 evaluated whether ataluren, a first-in-class investigational new drug, can restore dystrophin production in the muscle cells of patients with DMD whose disease is caused by a nonsense mutation.